More research is required to explore whether the nocebo effect on biosimilar switching may contribute to biologic treatment failure, specialists say. In a Review article in Rheumatology and Therapy, rheumatologists and gastroenterologists from five countries including Australia called for more robust and well-designed nonmedical switching studies. The nocebo effect was defined as disease worsening or ...
We need to know more about the nocebo effect in biosimilar switching
By Mardi Chapman
30 Jan 2020